Takeda sheds US rights to azilsartan products
This article was originally published in Scrip
Arbor Pharmaceuticals is to take over US sales and marketing activities for Takeda's azilsartan medoxomil-containing antihypertensive products, with the Japanese firm saying that it wants to focus commercial resources in this market on other recent and upcoming launches.
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.